Price
$0.71
Decreased by -2.59%
Dollar volume (20D)
1.72 M
ADR%
13.73
Earnings report date
Aug 8, 2024
Shares float
532.01 K
Shares short
268.15 K [50.40%]
Shares outstanding
4.08 M
Market cap
2.98 M
Beta
5.12
Price/earnings
N/A
20D range
0.70 1.38
50D range
0.67 5.60
200D range
0.67 22.93

Aptevo Therapeutics Inc., a clinical-stage research and development biotechnology company, focuses on developing immunotherapeutic candidates for the treatment of various forms of cancer in the United States.

It develops its products using ADAPTIR and ADAPTIR-FLEX platforms to generate monospecific, bispecific, and multi-specific antibody candidates capable of enhancing the human immune system against cancer cells.

The company's lead clinical blood cancer candidate is APVO436 that is in Phase 1b/2 clinical trial for acute myelogenous leukemia.

It is also developing ALG.APV-527, a novel investigational bispecific ADAPTIR candidate that is in Phase 1 clinical trial for NSCLC, head and neck, colorectal, pancreatic, breast, and other solid tumors; APVO603, a preclinical dual agonist bispecific ADAPTIR candidate for multiple solid tumors; APVO442, a novel bispecific candidate based on the ADAPTIR-FLEX platform technology for multiple solid tumors; and APVO711, a preclinical dual mechanism bispecific ADAPTIR candidate for prostate cancer.

The company has a collaboration and option agreement with Alligator Bioscience AB to develop ALG.APV-527.

Aptevo Therapeutics Inc. was incorporated in 2016 and is headquartered in Seattle, Washington.

  • Quarterly earnings
  • Annual earnings
Reported date EPSChange YoY EstimateSurprise
May 8, 24 -9.95
Decreased by -2.65 K%
-12.84
Increased by +22.51%
Mar 5, 24 -6.16
Decreased by -548.42%
-18.04
Increased by +65.85%
Nov 14, 23 -0.50
Increased by +66.67%
-0.75
Increased by +33.33%
Aug 10, 23 -1.23
Decreased by -122.04%
-1.12
Decreased by -9.82%
May 11, 23 0.39
Increased by +125.16%
-1.18
Increased by +133.05%
Mar 30, 23 -0.95
Increased by +25.20%
-1.53
Increased by +37.91%
Nov 10, 22 -1.50
Decreased by -4.90%
-1.64
Increased by +8.54%
Aug 11, 22 5.58
Increased by +418.86%
-1.33
Increased by +519.55%
  • Quarterly financials
  • Annual financials
Fiscal ending date RevenueChange YoY IncomeChange YoY ProfitChange YoY
Dec 31, 23 0.00
Increased by +100.00%
-5.90 M
Decreased by -119.45%
Decreased by N/A%
Decreased by N/A%
Sep 30, 23 0.00
Decreased by N/A%
-6.33 M
Increased by +17.41%
Decreased by N/A%
Decreased by N/A%
Jun 30, 23 0.00
Decreased by N/A%
-7.95 M
Decreased by -112.53%
Decreased by N/A%
Decreased by N/A%
Mar 31, 23 0.00
Decreased by -100.00%
11.41 M
Increased by +214.55%
Increased by +N/A%
Increased by +N/A%
Dec 31, 22 -3.11 M
Decreased by -184.97%
30.35 M
Increased by +583.93%
Decreased by -974.69%
Decreased by -469.56%
Sep 30, 22 0.00
Decreased by -100.00%
-7.67 M
Decreased by -9.60%
Decreased by N/A%
Decreased by N/A%
Jun 30, 22 0.00
Decreased by -100.00%
63.43 M
Increased by +899.71%
Increased by +N/A%
Increased by +N/A%
Mar 31, 22 3.11 M
Increased by +28.62%
-9.96 M
Decreased by -37.28%
Decreased by -319.88%
Decreased by -6.73%
Open dropdown content
Open dropdown content
DAILY
WEEKLY
MONTHLY